Medipal and JCR dose first patient in JR-446 Phase I/II trial
Medipal Holdings and JCR Pharmaceuticals said the first participant was dosed in their global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.